Patents Assigned to LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD.
  • Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors
    Patent number: 11639355
    Abstract: Disclosed is a novel class of MDM2-p53 inhibitor compounds having an imidaxopyrolone structure, and specifically disclosed are compounds represented by formulas (I-1) and (I-2) and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: May 2, 2023
    Assignees: LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD., SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD., MEDSHINE DISCOVERY INC.
    Inventors: Kevin X Chen, Xiaobing Yan, Jianglei Huang, Yuekun Nie, Guoping Hu, Jian Li, Shuhui Chen, Jiaqiang Dong, Tie-Lin Wang
  • Crystal form of estrogen receptor inhibitor and preparation method therefor
    Patent number: 11034653
    Abstract: Disclosed are a crystal form of an estrogen receptor inhibitor and a preparation method therefor, in particular disclosed are a crystal form A of a compound of formula (I) and a preparation method therefor, and the use of the crystal form in the preparation of a drug for treating breast cancer.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: June 15, 2021
    Assignees: LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD., SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.
    Inventors: Huijun He, Jianyu Lu, Weidong Li, Shenyi Shi, Zhijuan Chen, Charles Z. Ding, Lihong Hu, Tie-Lin Wang, Jiaqiang Dong
  • Indolo substituted piperidine compound as estrogen receptor down-regulator
    Patent number: 10774081
    Abstract: Disclosed in the present invention is a type of indole substituted piperidine compounds as an estrogen receptor down-regulator. Specifically disclosed are a compound as shown in formula (I), a pharmaceutically acceptable salt, hydrate or prodrug thereof, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof as an estrogen receptor down-regulator in the treatment of estrogen receptor positive breast cancers.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: September 15, 2020
    Assignees: LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD., SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.
    Inventors: Jianyu Lu, Charles Z. Ding, Xu Zeng, Huijun He, Shuhui Chen, Lihong Hu, Jiaqiang Dong, Tie-Lin Wang
  • Substituted-indole-compounds as estrogen receptor down-regulators
    Patent number: 10519143
    Abstract: Disclosed is a new indole compound, in particular, the compound as shown in formula (I), and a preparation method, pharmaceutical composition and use thereof as an estrogen receptor down-regulator in preparing drugs for treating estrogen receptor-positive breast cancer.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: December 31, 2019
    Assignee: LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD.
    Inventors: Jianyu Lu, Charles Z. Ding, Lihong Hu, Huijun He, Shuhui Chen, Jiaqiang Dong, Tie-Lin Wang
  • INDOLO SUBSTITUTED PIPERIDINE COMPOUND AS ESTROGEN RECEPTOR DEGRADING AGENT
    Publication number: 20190337938
    Abstract: Disclosed in the present invention is a type of indole substituted piperidine compounds as an estrogen receptor degrading agent. Specifically disclosed are a compound as shown in formula (I), a pharmaceutically acceptable salt, hydrate or prodrug thereof, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof as an estrogen receptor degrading agent in the treatment of estrogen receptor positive breast cancers.
    Type: Application
    Filed: October 30, 2017
    Publication date: November 7, 2019
    Applicants: LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD., SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.
    Inventors: Jianyu LU, Charles Z. DING, Xu ZENG, Huijun HE, Shuhui CHEN, Lihong HU, Jiaqiang DONG, Tie-Lin WANG